Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors

Parthenon Therapeutics has announced that a collaboration between the company, The University of Texas Health Center at Houston and George Washington University has demonstrated that PRTH-101 potently inhibits the adhesion of collagen receptor discoid in domain receptor-1 expressing cancer cells to collagen substrates and DDR1 autophosphorylation induced by collagen. The drug candidate binds to ..